[b]ARCW[/b] TODAY: ARC MIM Wins Metal Injection Molding Awards
Date : 06/02/2014 @ 7:00AM
Source : PR Newswire (US)
Stock : Arc Grp. Worldwide, Inc. (M
Arc Grp. Worldwide, Inc. (MM) (NASDAQ:ARCW)
Intraday Stock Chart
Today : Monday 2 June 2014
Click Here for more Arc Grp. Worldwide, Inc. (MM) Charts.
DELAND, Fla., June 2, 2014 /PRNewswire/ -- ARC Group Worldwide, Inc. (NASDAQ: ARCW), a leading global provider of advanced manufacturing and 3D printing solutions, announced today its ARC MIM company, won three MIM awards at the Metal Powder Industries Federation ("MPIF") World Congress on May 20, 2014.
FloMet, an ARC MIM company, earned the Grand Prize in the Medical/Dental Category for two 5 millimeter tines – one fixed, one moving – that go into a thermal tissue fusion and dissection system for a major medical OEM customer. The system utilizes direct thermal energy and pressure to effectively seal, transect, dissect, and coagulate tissue. Fabricated via MIM from 17-4 PH stainless steel, the tines overcame many molding and processing challenges, including the fixed tine's length and thin-rib requirements, as well as the need for straightness over its entire length for full functionality with mating components. Highly innovative tooling and advanced thermal processing techniques were employed to produce two components in a final as-assembled condition with only minimal secondary operations. FloMet's expertise in MIM technology created a compelling case for the customer to redesign the product away from its legacy manufacturing process.
FloMet also won the Grand Prize in the Electronic/Electrical Components Category with a three-piece assembly, including a nozzle interface, outer nozzle, and metal collar. The MIM components were for a leading consumer electronics company, used in their high-end, sound isolating earphones that enable user-customizable frequency responses. Made via MIM from 316L stainless steel, the components achieved the objective of
Sentiment: Strong Buy
HDY NEWS: "Force Majeure event" happening. "Tullow asserts Force Majeure event on offshore Guinea project"
"Hyperdynamics announced that Tullow Guinea asserted on March 11, to the Government of Guinea and members of the Consortium its claim that there has been a Force Majeure event under the Production Sharing Contract, or PSC, and the Joint Operating Agreement, or JOA. The members of the Consortium and their participating interests in the concession from the government of Guinea granting exploration rights offshore Guinea are Tullow - 40%, Hyperdynamics' subsidiary, SCS Corporation – 37% and Dana Petroleum (E&P) Limited – 23%. Tullow states in its notice that the decisions by the U.S. Department of Justice and the SEC to open investigations into the activities of Hyperdynamics in obtaining and retaining the concession rights constitute a Force Majeure event under the terms of the PSC and JOA. Tullow states in its notice that the asserted Force Majeure event prevents Tullow from performing its contractual obligations under the PSC. [b]Hyperdynamics is unable to predict the outcome or timing of the results of Tullow's assertion of the Force Majeure." [/b]
Another negative SA article about DDD: http://seekingalpha.com/article/2045533-3d-systems-is-a-great-short-and-heres-why?isDirectRoadblock=false&source=email_rt_article_readmore&uprof=51
"UPDATE: Bank of America Downgrades 3D Systems as Margin Trajectory is Problematic
8:56a ET February 24, 2014 (Benzinga)
In a report published Monday, Bank of America analyst Wamsi Mohan downgraded the rating on 3D Systems [b](NYSE: DDD) from Buy to Underperform, and lowered the price target from $90.00 to $65.00.
In the report, Bank of America noted, “We are downgrading shares of 3D Systems to Underperform with a PO of $65 for the following reasons (1) Organic growth rate peaking in 2014 and incremental topline growth will come at the expense of margins, (2) We view the increased investments as a catchup in spend necessary to stay competitive rather than driving incremental growth, (3) A lot of the M&A while additive to near term growth, in our opinion, will result in diluting LT organic growth and adds integration and execution risk in the interim, (4) A lot of high profile partnerships sound exciting (Motorola Mobility, Hasbro, Hershey's etc.) but success will be predicated on widespread adoption and margin performance driven by such ventures will likely be challenged.”
3D Systems closed on Friday at $80.74."
It has already reached the NEW price target then, so not much room for the price to rise from the current $95.
What is the upside on a stock that has a 200 P/E ratio, and only a 25% growth rate according to Yahoo over the next 5 years. I have 2 3D stocks and all 3D stocks seem to be a bit overpriced. Just a time to be careful for me. Good luck to all.
SA article predicts 80% drop? http://seekingalpha.com/article/1930501-3-Stocks-Which-Could-Fall-80-percent-In-2014?source=yahoo
"Lastly, I think 3D Systems (DDD) shares are ripe for a significant decline after rocketing +160% during 2013. There are few things which have captured the market's attention like 3D printing. DDD Systems is believed to be the 800 lb. gorilla of the 3D printing industry. With $510 million in revenue expected for 2013, 3D systems trades at 19x revenue and nearly 100x operating profit. Multiples like this imply: 1) sustained period of super-normal growth for at least a decade (2) maintaining and/or increasing operating margins for the foreseeable future (3) a business with a strong moat/stable competitive environment. I have concerns regarding all three of these points. Firstly, as I noted above, 3D printing will prove to be a highly cyclical industry given the industry given that it sells mainly to industrial companies with highly variable capital expenditure budgets. Growth can slow for industry or company specific reasons including increased competition and new technologies super-ceding capabilities of existing players like 3D systems. Further, I think the company's roll-up strategy will end up leading to many key employees from acquired companies leaving to start their own new 3D printing companies leading to new competitors with strong industry knowledge and customer relationships.
Let's explore these concerns. While I don't see any impropriety in the company's accounting methodology, R&D understated. In 2012, 3D systems spent just $23.5 million or 6.6% of revenue on R&D (just over 10% looking at R&D divided by printer + consumable sales). This certainly doesn't sound like an insurmountable obstacle for competitors. However, 3D Systems has made several acquisitions, acquiring technology in the process. However, this isn't captured in the income statement (though it does siphon off cash flow, the only thing that really matters in the va
One incredibly attractive selling point of Silver Wheaton is that it negotiates all of its contracts over the long term at a low fixed cost. Because of these contracts, Silver Wheaton is able to purchase most of its silver at a fraction more than $4 per ounce and gold at around $400 per ounce, then turn around and profit from the difference between these prices and current silver and gold spot pricing. It would take a huge drop in metal prices for Silver Wheaton not to be wildly profitable.
Silver Wheaton is also absolved from any additional mine costs beyond its up-front payment and perhaps build-out milestone installments. Upkeep and maintenance, as well as future expansion, are fully the responsibility of the mine owner and not Silver Wheaton.
With predictable costs, a decent yield of 1.8%, and long-term built-in cash flow, there aren't
SNTA is working on several drug candidates that have been discovered and developed internally in SNTA's labs and has HUGE potential for investors.
SNTA possesses a unique chemical compound library, consisting of proprietary compounds collected over two decades from industrial and academic sources that are not typically found at pharmaceutical firms, even larger more well-known pharmaceutical behemoths. Using this library of compounds, researchers use a variety of biochemical and molecular techniques to generate and optimize promising lead compounds and generate new drug candidates that can enter the drug development process. Most compounds do not make it past the preliminary stages, but some of the most successful drugs will, eventually leading to human trials and full blown randomized clinical trials. As an epidemiologist, I am very familiar with this process. SNTA currently has an impressive 800 issued patents and pending applications worldwide. SNTA's leading candidate drug is the anti-breast, colorectal, lung and hemolytic cancer drug ganetespib, which has real potential to come to market.
Sentiment: Strong Buy
23m in revenues and .53 eps next year is the Yahoo average estimates for next year based on 3 analysts. A 20 p/e would price this at around $10, based on next year's .53 estimates. Do you have the link for your statement that we all could see duh??
is the Yahoo average estimates for next year based on 3 analysts. A 20 p/e would price this at around $10, based on next year's .53 estimates.
Sentiment: Strong Buy
It has a product, has revenues, and that alone is more than MANY MANY other pharmas out there
IMO it SHOULD get back to $2 - $2,50 levels soon
LF: "Time to take a "Leap" of faith?
Of course, if it's growth you seek, you need look no further than one of the stocks Wall Street is down grading today to find it. Earlier this week, games maker LeapFrog enterprises beat earnings estimates soundly with a third-quarter report featuring $0.38 per share in profits -- $0.06 better than Wall Street had anticipated. Projections for the future likewise outpaced expectations, with LeapFrog predicting it will earn at least $0.36 per share this year, and perhaps as much as $0.46.
Regardless, analysts at Imperial Capital announced this morning that they are downgrading the stock to "in-line." Why?
According to Imperial, "an increasingly challenging consumer spending environment" and expected "highly promotional and competitive holiday season" all augur poorly for LeapFrog's profits in the current quarter. Although long-term, Imperial remains optimistic about the stock, the analyst is cutting $0.20 per share off its earnings estimates for both this year and next, reducing 2013 estimates to $0.44 per share, and 2014 estimates to $0.55.
If Imperial is right about that, then LeapFrog's current 5.6 "P/E ratio" may not be as big of a bargain as it looks. The $0.44 in earnings per share this year could soon have the stock valued at a P/E of 17.5 (if the stock price does not change), or a slightly less pricey 14 times forward earnings valuation.
And yet, even if Imperial is right about LeapFrog's earnings, I still think the stock's cheap enough to own. Moving from $0.44 to $0.55 in the space of a year implies 25% annualized earnings growth -- more than enough to justify a 17.5 P/E. Indeed, even the more conservative consensus projection for LeapFrog -- 17.5% long-term growth, according to Yahoo! Finance data -- should justify today's price.
Long story short, LeapFrog may not be as big of a bargain as it appears on the surface. But it's still a big enough bargain to buy."
from the article http://finance.yahoo.com/news/synta-pharma-slumps-data-cancer-194755607.html